MedTrace Logo

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

NCT06533332 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Conditions

Interventions

DRUG

ERX-315

Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.

Sponsors & Collaborators

  • EtiraRx Australia Pty Ltd

    lead OTHER

Principal Investigators

  • Rasha Cosman, MBBS · The Kinghorn Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2025-12-30
Completion
2026-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533332 on ClinicalTrials.gov